Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Urogenital Neoplasms » Genital Neoplasms, Female
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urogenital Neoplasms » Genital Neoplasms, Female
Diseases [C] » Urogenital Diseases [C12] » Urogenital Neoplasms » Genital Neoplasms, Female
Description
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE). MeSH
Hierarchy View
Subtype Terms (5)
Fallopian Tube Neoplasms
315 drugs (131 approved, 184 experimental)
Ovarian Neoplasms
863 drugs (254 approved, 609 experimental)
Uterine Neoplasms
106 drugs (73 approved, 33 experimental)
Vaginal Neoplasms
44 drugs (27 approved, 17 experimental)
Vulvar Neoplasms
63 drugs (39 approved, 24 experimental)
Phase 4 Indicated Drugs (4)
Phase 3 Indicated Drugs (22)
Phase 2 Indicated Drugs (22)
Phase 1 Indicated Drugs (19)
Other Experimental Indicated Drugs (9)
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (15)
Organization Involved with Phase 2 Indications (22)
Organization Involved with Phase 1 Indications (18)
Organization Involved with Other Experimental Indications (6)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
